logo

Global Human Growth Hormone (HGH) Market Size (2024 - 2029)

The human growth hormone market is experiencing significant growth, driven by the increasing prevalence of pituitary dysfunctions and the rising off-label use of growth hormones. The market's expansion is further supported by advancements in recombinant human growth hormone therapies, which are crucial for treating deficiencies caused by conditions such as Prader-Willi syndrome and Turner syndrome. These developments are enhancing the management of growth hormone deficiency disorders, leading to greater awareness and utilization of these therapies. Additionally, ongoing research and development efforts aimed at creating long-acting hormonal therapies with fewer side effects are expected to propel the market forward during the forecast period.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Hormones Research Human Growth Hormone Industry Market Size

Market Size of Global Human Growth Hormone (HGH) Industry

Human Growth Hormone (HGH) Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 8.61 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Human Growth Hormone (HGH) Market Major Players

*Disclaimer: Major Players sorted in no particular order

Human Growth Hormone Market Analysis

The human growth hormone market registered a market size of USD 4,632.54 million in 2020, and it is expected to reach USD 7,567.74 million by 2026, registering a CAGR of 8.61% during the forecast period, 2021-2026.

According to a research article by Mohamed Hamdy Elkarow et al., published in the Frontiers in Endocrinology Journal November 2020, patients with decreased growth hormone secretion constitute a risk factor for COVID-19 severity, which requires attention toward preventive measures in susceptible individuals.

In addition, patients with Prader-Willi syndrome should take extra precautions to minimize the risk of getting COVID-19. Moreover, Prader-Willi syndrome patients may not show typical symptoms such as a high temperature, and they may also experience a higher-than-normal pain threshold, which may delay the diagnosis of COVID-19.

The major factors driving the market growth include the development of recombinant human growth hormone drugs, rise in pituitary dysfunction cases, and rising off-label use of human growth hormones.

In humans, the growth hormone deficiency is caused when the pituitary gland does not synthesize enough concentration of human growth hormones. This deficiency is treated by administering recombinant human growth hormones by subcutaneous injection. Various genetic disorders such as Prader-Willi syndrome and Turner syndrome may also cause growth hormone deficiency, leading to delayed puberty and shorter-than-average height.

Turner syndrome, also known as congenital ovarian hypoplasia syndrome, occurs when the X chromosome is partially or completely missing in females. According to a research article by Xiaoxiao Cui et al., published in the Intractable & Rare Diseases Research Journal 2018, globally, Turner syndrome (TS) is a relatively common type of human chromosomal aberration that occurs in 1:2,500 live female births.

The human growth hormone helps to stimulate regeneration, reproduction, and growth. Rising use of growth hormones and awareness about growth hormones, which helps in the management of growth hormone deficiency disorders, are boosting the market growth.

Furthermore, most companies are investing in R&D to develop a growth hormone that has fewer side effects and will be a long-acting hormonal therapy. In addition, the rapid development of new novel recombinant human growth hormones is expected to drive the human growth hormone market over the forecast period.

Human Growth Hormone Industry Segmentation

As per the scope of the report, the human growth hormone, also known as somatotropin, is a peptide hormone that stimulates growth, cell reproduction, and cell regeneration. The human growth hormone (HGH) market is segmented by application (growth hormone deficiency, Turner syndrome, idiopathic short stature, Prader-Willi syndrome, and other applications), distribution channel (hospitals and retail pharmacies, online pharmacies, and other distribution channels), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

By Application
Growth Hormone Deficiency
Turner Syndrome
Idiopathic Short Stature
Prader-Willi Syndrome
Other Applications
By Distribution Channel
Hospitals and Retail Pharmacies
Online Pharmacies
Other Distribution Channels
Geography
North America
United States (By Application and Distribution Channel)
Canada (By Application and Distribution Channel)
Mexico (By Application and Distribution Channel)
Europe
Germany (By Application and Distribution Channel)
United Kingdom (By Application and Distribution Channel)
France (By Application and Distribution Channel)
Italy (By Application and Distribution Channel)
Spain (By Application and Distribution Channel)
Rest of Europe (By Application and Distribution Channel)
Asia-Pacific
China (By Application and Distribution Channel)
Japan (By Application and Distribution Channel)
India (By Application and Distribution Channel)
Australia (By Application and Distribution Channel)
South Korea (By Application and Distribution Channel)
Rest of Asia-Pacific (By Application and Distribution Channel)
Middle-East and Africa
GCC (By Application and Distribution Channel)
South Africa (By Application and Distribution Channel)
Rest of Middle-East and Africa (By Application and Distribution Channel)
South America
Brazil (By Application and Distribution Channel)
Argentina (By Application and Distribution Channel)
Rest of South America (By Application and Distribution Channel)
Need A Different Region Or Segment?
Customize Now

Global Human Growth Hormone (HGH) Market Size Summary

The human growth hormone market is experiencing significant expansion, driven by advancements in recombinant human growth hormone drugs and an increase in cases of pituitary dysfunction. This growth is further fueled by the rising off-label use of these hormones, which are essential for treating deficiencies caused by conditions such as Prader-Willi syndrome and Turner syndrome. These genetic disorders, characterized by growth hormone deficiencies, lead to delayed puberty and shorter-than-average height, necessitating the use of growth hormones for effective management. The market is also benefiting from heightened awareness and early diagnosis initiatives, supported by various public and private organizations, which are crucial in managing these conditions and boosting demand for treatment.

In the United States, the market is bolstered by robust research and development activities, favorable reimbursement policies, and a well-established healthcare infrastructure. The impact of COVID-19 on access to medical care and therapies for individuals with Prader-Willi syndrome has highlighted the importance of continued research and support for these patients. The market is moderately consolidated, with key players like Pfizer Inc., Eli Lilly and Company, and Novo Nordisk AS leading the charge in developing more efficacious and long-acting human growth hormone therapies. Ongoing clinical trials and partnerships among these companies are expected to drive further growth, as they work towards creating treatments with fewer side effects and improved outcomes for patients with growth hormone deficiencies.

Explore More

Global Human Growth Hormone (HGH) Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Development of Recombinant Human Growth Hormone Drugs

      2. 1.2.2 Rise in Pituitary Dysfunction Cases

      3. 1.2.3 Rising Off-label Use of Human Growth Hormones

    3. 1.3 Market Restraints

      1. 1.3.1 Adverse Effects Associated with Human Growth Hormones

      2. 1.3.2 Stringent Regulatory Processes

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Application

      1. 2.1.1 Growth Hormone Deficiency

      2. 2.1.2 Turner Syndrome

      3. 2.1.3 Idiopathic Short Stature

      4. 2.1.4 Prader-Willi Syndrome

      5. 2.1.5 Other Applications

    2. 2.2 By Distribution Channel

      1. 2.2.1 Hospitals and Retail Pharmacies

      2. 2.2.2 Online Pharmacies

      3. 2.2.3 Other Distribution Channels

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States (By Application and Distribution Channel)

        2. 2.3.1.2 Canada (By Application and Distribution Channel)

        3. 2.3.1.3 Mexico (By Application and Distribution Channel)

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany (By Application and Distribution Channel)

        2. 2.3.2.2 United Kingdom (By Application and Distribution Channel)

        3. 2.3.2.3 France (By Application and Distribution Channel)

        4. 2.3.2.4 Italy (By Application and Distribution Channel)

        5. 2.3.2.5 Spain (By Application and Distribution Channel)

        6. 2.3.2.6 Rest of Europe (By Application and Distribution Channel)

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China (By Application and Distribution Channel)

        2. 2.3.3.2 Japan (By Application and Distribution Channel)

        3. 2.3.3.3 India (By Application and Distribution Channel)

        4. 2.3.3.4 Australia (By Application and Distribution Channel)

        5. 2.3.3.5 South Korea (By Application and Distribution Channel)

        6. 2.3.3.6 Rest of Asia-Pacific (By Application and Distribution Channel)

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC (By Application and Distribution Channel)

        2. 2.3.4.2 South Africa (By Application and Distribution Channel)

        3. 2.3.4.3 Rest of Middle-East and Africa (By Application and Distribution Channel)

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil (By Application and Distribution Channel)

        2. 2.3.5.2 Argentina (By Application and Distribution Channel)

        3. 2.3.5.3 Rest of South America (By Application and Distribution Channel)

Global Human Growth Hormone (HGH) Market Size FAQs

The Global Human Growth Hormone (HGH) Market is projected to register a CAGR of 8.61% during the forecast period (2024-2029)

AnkeBio Co. Ltd, Eli Lilly and Company, Ferring BV, Novo Nordisk AS and Ipsen S.A. are the major companies operating in the Global Human Growth Hormone (HGH) Market.

Growth Hormone Market Report Snapshots

Human Growth Hormone Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)